Immunome completed the merger with Morphimmune in a $125m deal.

Immunome, a biotechnology company with a growing pipeline of cancer immunotherapies fueled by the human immune system, completed the merger with Morphimmune, a biotechnology company focused on developing targeted oncology therapeutics, in a $125m deal. “This merger is an essential step in establishing a preeminent oncology company. We believe that we are well positioned to advance our current oncology pipeline into the clinic, build upon the pipeline through our technology platform and proprietary toolbox, and expand our portfolio through strategic transactions focused on clinical and preclinical assets,” Clay Siegall, Morphimmune President and CEO.